14-day Premium Trial Subscription Try For FreeTry Free

Information

500 River Ridge Drive

Norwood MA 02062

617 963 0100

www.corbuspharma.com

Industry: Biotechnology

Sector: Healthcare

Corbus Pharmaceuticals Holdings

Description

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Click to get the best stock tips daily for free!
GOLDEN STAR
Ticker Change Signal Date
WEC
$95.99
1.68% Nov 06
K
$80.97
0.0618% Nov 06
AGR
$35.59
0.93% Nov 06
AMRX
$8.50
2.71% Nov 06
F
FALN
$26.99
0.704% Nov 06

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE